Warning Letter — Calibrate IV Hydration
The FDA issued a Warning Letter to Calibrate IV Hydration following an evaluation by the Center for Biologics Evaluation and Research (CBER). The source indicates the letter was issued on October 13, 2026, though specific regulatory violations are not detailed in the provided excerpt.
This affects Calibrate IV Hydration, as well as clinical staff and regulatory professionals involved in the administration and oversight of intravenous biological products.
The involvement of CBER suggests that the warning likely pertains to the unauthorized distribution or administration of biological products without proper licensure or investigational oversight. For regulatory professionals, this emphasizes the FDA's continued scrutiny of the IV hydration industry, particularly when biological components are involved. The source provides limited detail on the specific infractions, but CBER enforcement generally signals concerns regarding product safety, purity, or manufacturing standards for biologics.
Regulatory and clinical teams should review the licensure status of all biological products administered in clinical settings. QA departments should ensure that any intravenous treatments involving biological components have received necessary FDA approvals or are operating under an active Investigational New Drug (IND) application.
FDA Warning Letter issued to: Calibrate IV Hydration. 10/13/2026 — Center for Biologics Evaluation and Research (CBER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/calibrate-iv-hydration-729846-10132026
Open in openFDA / FDA.gov